JPWO2021157650A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021157650A5 JPWO2021157650A5 JP2021575856A JP2021575856A JPWO2021157650A5 JP WO2021157650 A5 JPWO2021157650 A5 JP WO2021157650A5 JP 2021575856 A JP2021575856 A JP 2021575856A JP 2021575856 A JP2021575856 A JP 2021575856A JP WO2021157650 A5 JPWO2021157650 A5 JP WO2021157650A5
- Authority
- JP
- Japan
- Prior art keywords
- substituent
- pharmaceutical composition
- inhibitor
- composition according
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001424 substituent group Chemical group 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 239000012664 BCL-2-inhibitor Substances 0.000 claims 9
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims 9
- 229940124291 BTK inhibitor Drugs 0.000 claims 7
- 230000002441 reversible effect Effects 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 5
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 claims 4
- 229950004847 navitoclax Drugs 0.000 claims 4
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical group C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 4
- 229960001183 venetoclax Drugs 0.000 claims 4
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- CVCLJVVBHYOXDC-IAZSKANUSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole Chemical compound COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C CVCLJVVBHYOXDC-IAZSKANUSA-N 0.000 claims 1
- ZVAGBRFUYHSUHA-LZOXOEDVSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole;methanesulfonic acid Chemical compound CS(O)(=O)=O.COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C ZVAGBRFUYHSUHA-LZOXOEDVSA-N 0.000 claims 1
- LJODJUIHONTDMR-UHFFFAOYSA-N 2-[3-[2-amino-6-[1-(oxetan-3-yl)-3,6-dihydro-2H-pyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2-(hydroxymethyl)phenyl]-6-cyclopropyl-8-fluoroisoquinolin-1-one Chemical compound Nc1nc(-c2cccc(c2CO)-n2ccc3cc(cc(F)c3c2=O)C2CC2)c2cc([nH]c2n1)C1=CCN(CC1)C1COC1 LJODJUIHONTDMR-UHFFFAOYSA-N 0.000 claims 1
- RQYDQAPLARKISN-UHFFFAOYSA-N 2-[3-[4-amino-6-[(1-methylpyrazol-4-yl)amino]-1,3,5-triazin-2-yl]-2-(hydroxymethyl)phenyl]-6-cyclopropyl-8-fluoroisoquinolin-1-one Chemical compound C1=NN(C)C=C1NC1=NC(N)=NC(C=2C(=C(C=CC=2)N2C(C3=C(F)C=C(C=C3C=C2)C2CC2)=O)CO)=N1 RQYDQAPLARKISN-UHFFFAOYSA-N 0.000 claims 1
- QIOCQCYXBYUYLH-YACUFSJGSA-N 3-[1-[(3r)-3-[4-[[4-[4-[3-[2-(4-chlorophenyl)-5-methyl-4-methylsulfonyl-1-propan-2-ylpyrrol-3-yl]-5-fluorophenyl]piperazin-1-yl]phenyl]sulfamoyl]-2-(trifluoromethylsulfonyl)anilino]-4-phenylsulfanylbutyl]piperidine-4-carbonyl]oxypropylphosphonic acid Chemical compound CC(C)N1C(C)=C(S(C)(=O)=O)C(C=2C=C(C=C(F)C=2)N2CCN(CC2)C=2C=CC(NS(=O)(=O)C=3C=C(C(N[C@H](CCN4CCC(CC4)C(=O)OCCCP(O)(O)=O)CSC=4C=CC=CC=4)=CC=3)S(=O)(=O)C(F)(F)F)=CC=2)=C1C1=CC=C(Cl)C=C1 QIOCQCYXBYUYLH-YACUFSJGSA-N 0.000 claims 1
- 229940126177 ABBV-167 Drugs 0.000 claims 1
- -1 AZD-0466 Chemical compound 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- FNBXDBIYRAPDPI-BHVANESWSA-N O1[C@H](COCC1)CNC1=C(C=C(C=C1)S(=O)(=O)NC(C1=C(C=C(C=C1)N1CCN(CC1)CC1=C(CC2(CCC2)CC1)C1=CC=C(C=C1)Cl)OC=1C=C2C(=NC=1)NC=C2)=O)[N+](=O)[O-] Chemical compound O1[C@H](COCC1)CNC1=C(C=C(C=C1)S(=O)(=O)NC(C1=C(C=C(C=C1)N1CCN(CC1)CC1=C(CC2(CCC2)CC1)C1=CC=C(C=C1)Cl)OC=1C=C2C(=NC=1)NC=C2)=O)[N+](=O)[O-] FNBXDBIYRAPDPI-BHVANESWSA-N 0.000 claims 1
- CLQLTQZFOGFNCT-UHFFFAOYSA-N [5-[5-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-[[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylcarbamoyl]phenoxy]pyrrolo[2,3-b]pyridin-7-yl]methyl dihydrogen phosphate Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CN=C3N(COP(O)(O)=O)C=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 CLQLTQZFOGFNCT-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229950006584 obatoclax Drugs 0.000 claims 1
- 229960005554 obatoclax mesylate Drugs 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims 1
Claims (15)
- 前記可逆的BTK阻害剤が、Qが構造(a)であり、R1がヒドロキシメチル基であるオキソイソキノリン誘導体又はその薬学的に許容される塩である、請求項1に記載の薬剤組成物。
- 前記可逆的BTK阻害剤が、Z1がヒドロキシメチル基であるトリアジン誘導体又はその薬学的に許容される塩である、請求項5に記載の薬剤組成物。
- 前記BCL-2阻害剤が、ベネトクラックス、ナビトクラックス、オバトクラックス、オバトクラックスメシル酸塩、サブトクラックス、APG-1252、AZD-0466、APG-2575、ABBV-167、S-65487又はS-55746である、請求項1~7のいずれか一項に記載の薬剤組成物。
- 前記BCL-2阻害剤が、ベネトクラックスである、請求項8に記載の薬剤組成物。
- 前記BCL-2阻害剤が、ナビトクラックスである、請求項8に記載の薬剤組成物。
- 前記BCL-2阻害剤が、ベネトクラックスである、請求項4に記載の薬剤組成物。
- 前記BCL-2阻害剤が、ナビトクラックスである、請求項4に記載の薬剤組成物。
- 前記BCL-2阻害剤が、ベネトクラックスである、請求項7に記載の薬剤組成物。
- 前記BCL-2阻害剤が、ナビトクラックスである、請求項7に記載の薬剤組成物。
- 請求項1に記載の薬剤組成物を製造するための化合物(I)およびBCL-2阻害剤の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020018099 | 2020-02-05 | ||
PCT/JP2021/004083 WO2021157650A1 (ja) | 2020-02-05 | 2021-02-04 | 抗がん剤組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2021157650A1 JPWO2021157650A1 (ja) | 2021-08-12 |
JPWO2021157650A5 true JPWO2021157650A5 (ja) | 2024-02-13 |
Family
ID=77199359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021575856A Pending JPWO2021157650A1 (ja) | 2020-02-05 | 2021-02-04 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230100235A1 (ja) |
EP (1) | EP4101468A4 (ja) |
JP (1) | JPWO2021157650A1 (ja) |
CN (1) | CN115023240A (ja) |
WO (1) | WO2021157650A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230405006A1 (en) * | 2020-11-13 | 2023-12-21 | Carna Biosciences, Inc. | Combination pharmaceutical composition and treatment method |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201591656A1 (ru) * | 2013-04-08 | 2016-05-31 | Фармасайкликс Элэлси | Комбинированная терапия с ибрутинибом |
CN105683178B (zh) * | 2013-07-26 | 2019-04-12 | 卡尔那生物科学株式会社 | 三嗪衍生物 |
US9717745B2 (en) * | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
US20180207164A1 (en) * | 2015-08-03 | 2018-07-26 | Gilead Sciences, Inc. | Combination therapies for treating cancers |
KR102565546B1 (ko) * | 2016-11-25 | 2023-08-10 | 카나 바이오사이언스, 인코포레이션 | 신규 옥소이소퀴놀린 유도체 |
RU2019127350A (ru) * | 2017-02-03 | 2021-03-03 | ЭйАй ТЕРАПЬЮТИКС, ИНК. | Способы лечения рака с использованием ингибиторов hsp90 |
US11891450B2 (en) * | 2018-02-12 | 2024-02-06 | Forty Seven, Inc. | Anti-CD47 agent-based treatment of CD20-positive cancer |
-
2021
- 2021-02-04 WO PCT/JP2021/004083 patent/WO2021157650A1/ja unknown
- 2021-02-04 CN CN202180012753.2A patent/CN115023240A/zh active Pending
- 2021-02-04 JP JP2021575856A patent/JPWO2021157650A1/ja active Pending
- 2021-02-04 US US17/796,814 patent/US20230100235A1/en active Pending
- 2021-02-04 EP EP21750742.5A patent/EP4101468A4/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011507854A5 (ja) | ||
JP2019534260A5 (ja) | ||
JP2019505541A5 (ja) | ||
JP2017511360A5 (ja) | ||
JP2004518651A5 (ja) | ||
RU2003136080A (ru) | Ингибирующие cdk-киназы пиримидины, способ их получения и их применение в качестве лекарственных средств | |
JP2017520607A5 (ja) | ||
CA2984259A1 (en) | Combinations of inhibitors of irak4 with inhibitors of btk | |
SI3106463T1 (en) | Compounds of substituted pyrazolo (1,5-) pyrimidine as inhibitors of TRK kinase | |
JP2020510015A5 (ja) | ||
JP2017524702A5 (ja) | ||
CA2571347A1 (en) | Piperazine derivatives for the treatment of female sexual disorders | |
JP2017528498A5 (ja) | ||
JP2005508336A5 (ja) | ||
CA2422354A1 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
JP2011507849A5 (ja) | ||
JP2007519694A5 (ja) | ||
JP2014514360A5 (ja) | ||
JP2012501312A5 (ja) | ||
JP2004525149A5 (ja) | ||
RU2007108539A (ru) | Производные 1, 2, 4-триазин-6-она, ингибирующие вич | |
JP2004535447A5 (ja) | ||
JP2016504290A5 (ja) | ||
RU2006126974A (ru) | Амидное производное и лекарственное средство |